SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
* SK bioscience's first mRNA vaccine candidate is expected to enter clinical trials inAustralia in February 2025, with interim results expected by 2026. * Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI. * SK bioscience will respond to...
SK bioscience Announces Approval of Its Quadrivalent Influenza Vaccine in Indonesia
* This approval paves the way for exports to the world's fourth most populous country. * SK bioscience aims to continue to grow as a global vaccine brand beyond Korea by leveraging the advantages of cell-cultured vaccines. SEONGNAM, South Korea, Oct. 23, 2024 /PRNewswire/ -- SK bioscience, a ...
SK bioscience Announces Approval of Its Quadrivalent Influenza Vaccine in Indonesia
* This approval paves the way for exports to the world's fourth most populous
country.
* SK bioscience aims to continue to grow as a global vaccine brand beyond
Korea. SEONGNAM, South Korea, Oct. 23, 2024 /PRNewswire/ -- SK bioscience
Korea's SK bioscience Acquires Stake in U.S. Biotech Fina Biosolutions
* SK bioscience invested USD 3 million in FinaBio, a U.S. company specializing in next-generation conjugate vaccine technology. * With the agreement, SK bioscience expects to improve the immunogenicity and productivity of conjugate vaccines, including those for pneumoniae and typhoid. * The ...
South Korea's SK bioscience Completes Acquisition of Germany's CDMO IDT Biologika
* SK bioscience completed the acquisition of German CDMO company IDT Biologika with over a century of history that enables immediate expansion in revenue and infrastructure. * The company aims to double sales of IDT Biologika by 2028 through new business projects and operational efficiency. ...
SK bioscience Exports Influenza Vaccine to Thailand, Entering Southern Hemisphere Market
* Company exported 440,000 doses to Thailand, marking its entry into the Southeast Asian market and the Southern Hemisphere market. * Company has obtained marketing authorizations in 12 countries, with additional approvals underway in 10 countries to expand its market worldwide. BANGKOK and S...
SK bioscience Presents Solution for Equitable Access of Vaccine at Regionalized Vaccine Manufacturing Collaborative of World Economic Forum
* Jaeyong Ahn, CEO of SK bioscience, presents the 'Glocalization' project to secure the global vaccine accessibility, claiming the importance of international cooperation to establish a regional-based vaccine hub at the Regionalized Vaccine Manufacturing Collaborative Side Event. SEONGNAM, Sout...
SK bioscience Announces the Largest Investment Ever to Establish Songdo Global Research & Process Development Center
* The additional investment for the 'R&PD Center' was confirmed by the board of directors committee with a total of261 million USD * SK bioscience plans to establish a vaccine-biopharmaceutical hub, organizing a global cooperative model against new pandemics SEONGNAM, South Korea, Feb. 8, 202...
SK bioscience Introduces New Partnership Model to Establish Regional Vaccine Hubs
* SK bioscience shared a development history of the South Korea's first COVID-19 vaccine at the Riyadh Global Medical Biotechnology Summit 2023 (RGBMS 2023) in theKingdom of Saudi Arabia(KSA) * SK bioscience also explained a new global partnership model aiming to promote public health in deve...
SK bioscience Appoints New Executives to Accelerate New Growth Strategies
* Two biopharmaceutical experts join SK bioscience to strengthen the future strategies * With recruitment of global talent and capabilities accumulated during the COVID-19 pandemic, SK bioscience will continue to achieve sustainable growth SEOUL, South Korea, Jan. 20, 2023 /PRNewswire/ -- SK ...
SK bioscience's Zoster Vaccine Receives Biologics License Application Approval in Malaysia
* The world-second developed shingles vaccine 'SKYZoster™' is approved by the National Pharmaceutical Regulatory Agency (NPRA) * SK biosciences plans to launch the zoster vaccine with proven efficacy and safety starting in Southeast Asian market SEOUL, South Korea, Jan. 9, 2023 /PRNewswire/ -...
SK bioscience and CEPI Sign Agreement to Develop mRNA Vaccines
* CEPI supports up to 40 mil. USD for early development of mRNA vaccine platform to SK bioscience; up to a further 100 mil. could be made available for late-stage development. * SK bioscience to secure new vaccines and establish pandemic response system * SK bioscience to enhance human healt...
SK bioscience Appoints New Executives towards Global Business Growth
* Global experts continue to join SK bioscience, while its U.S. corporate entity is being established * Company plans to strategically invest in personnel, innovation & infrastructure to ensure global competitiveness SEOUL, South Korea, Oct. 21, 2022 /PRNewswire/ -- SK bioscience, a global in...
